MHRA and NICE Launch Survey on Digital Mental Health Technologies Programme

Call for evidence runs from 5 November 2026 to 26 February 2027 to assess Phase 1 resources.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have launched a call for evidence on resources produced under the Wellcome-funded Digital Mental Health Technologies (DMHT) programme.

The survey opened on 5 November 2026 and will remain open until 26 February 2027. It forms part of the programme’s Phase 1 evaluation and is intended to assess how the resources have been received and used across the sector.

The resources were developed to support the safe development, regulation, evaluation and adoption of digital mental health technologies, including mental health apps and other digital tools. The MHRA and NICE are seeking feedback from developers and manufacturers, healthcare professionals, researchers, policymakers, regulators, people with lived experience of mental health conditions, carers and members of the public.

According to the two organisations, the survey is particularly interested in whether the materials have influenced users’ knowledge, confidence, decision-making and professional practice. Findings will help determine whether the Phase 1 outputs have achieved their intended objectives and will inform the future direction of Phase 2 of the DMHT programme.

The MHRA and NICE said stakeholders are encouraged to take part whether they have engaged extensively, minimally or not at all with the existing resources. Feedback will be used to identify strengths, highlight areas for improvement and shape future work intended to improve the safety and effectiveness of digital mental health technologies.

SM

Sonia Marchetti

Sonia Marchetti covers home blood pressure monitors, digital thermometers, and pulse oximeters as a home health devices analyst focused on product selection and use boundaries. Her evidence framework examines cuff fit, measurement repeatability, thermometer placement, battery behavior, and the intended scope of ISO 81060-2 for automated blood pressure validation without assuming any device has passed it. She helps private label managers, pharmacy buyers, and quality teams compare sample evidence, labeling claims, and maintenance needs while leaving individual readings and clinical decisions to qualified care professionals.